1. Australia Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Biotron Limited

Biotron Limited

BITRF
Biotron LimitedUS flagOther OTC
0.00
USD
- -
- -
1.81MMarket Cap
2012 Y
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
Revenue per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Basic EPS, GAAP
-0.01
-0.01
-0.01
-0.01
-0.01
-0.01
- -
- -
- -
- -
- -
- -
- -
Free Cash Flow per Basic Share
-0.01
-0.01
-0.01
-0.01
-0.01
-0.01
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
0.03
0.01
- -
0.01
0.01
- -
- -
0.01
0.01
- -
- -
- -
- -
Tangible Book Value per Share
0.03
0.01
- -
0.01
0.01
- -
- -
0.01
0.01
- -
- -
- -
- -
Basic Weighted Avg Shares
273
331
331
356
427
432
469
660
772
828
828
938
1,031
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Operating Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Depreciation Expense
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Net Income, GAAP
-2
-4
-3
-3
-3
-3
-2
-2
-4
-3
-3
-3
-3
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Working Capital
8
4
1
4
3
1
1
5
7
4
1
3
- -
LT Debt
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Total Equity
8
4
1
4
3
1
1
5
7
4
1
3
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
-59.21
-65.51
-128.03
-148.39
-118.29
-179.96
-172.89
-55.24
-59.34
-59.95
-116.76
-265.28
- -

Capital Structure

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
42.78%
-1.08%
-107.69%
Free Cash Flow
- -
- -
- -
Net Income, GAAP
7.64%
24.45%
-1.61%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2022
- -
- -
- -
- -
- -
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2022
- -
- -
- -
- -
- -
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2022
- -
- -
- -
- -
- -
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -

Company Description

APIChatGPT
CEO
Michelle Miller GCertAppFin
Full Time Employees
3
Sector
Healthcare
Industry
Biotechnology
Address
66 Hunter Street Sydney NSW Australia 2000
IPO Date
Mar 22, 2013
Website
biotron.com.au
Similar Companies
Pluri Inc. (PLUR)
GC Corp. (005257.KS)
NanoLogix, Inc. (NNLX)
Kintor Pharmaceutical Limited (9939.HK)
Bright Minds Biosciences Inc. (DRUG)
Entero Therapeutics, Inc. (ENTO)
Business
Biotron Limited (BITRF) is an Australian biotechnology company focused on developing antiviral therapeutics targeting the viral replication process. The company offers a pipeline of small molecule drugs, including BIT225, an investigational treatment for HIV that inhibits the virus's Vpu protein to enhance immune response; and other candidates targeting dengue fever, hepatitis C, and influenza through its proprietary mechanism targeting viral protein assembly. These products aim to address unmet needs in antiviral therapy by disrupting conserved viral processes rather than specific mutations, providing broad-spectrum potential; services include preclinical and clinical development stages across these programs. Biotron operates primarily in Australia with global development partnerships, founded in 2002 and headquartered in Melbourne. In recent developments, Biotron has advanced its clinical pipeline with ongoing Phase II trials for BIT225 in HIV patients, reporting positive interim data on viral load reduction and immune restoration within the last two years. The company secured additional funding through a capital raise in 2024 to support expanded trials and manufacturing scale-up for dengue and influenza candidates. No major acquisitions or name changes have occurred recently, but Biotron announced a strategic research collaboration with international academic institutions to accelerate preclinical studies for emerging viral threats.